Latest Headlines

Does Anemia Protect Children From Malaria?

It is well known that sickle cell trait can protect carriers from developing malaria; yet iron deficiency anemia offers a greater protective effect against malaria than sickle cell trait, according to research published in...

Online Exclusive

FDA Places Clinical Hold on Studies of Allogeneic CAR T-Cell Therapy

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on two phase I trials of gene-edited allogeneic chimeric antigen receptor (CAR)...

Hurricane Harvey Flooding Causes High Levels of Carcinogenic Substance

Flooding from Hurricane Harvey damaged an oil refinery in Houston, Texas, releasing dangerous amounts of the carcinogen benzene into the air. The compound is...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

pASHions: B.Y.O.B. (Build Your Own Boat) With Joseph H. Antin, MD

In more from our interview with Dr. Antin, he offers two simple rules for starting a new hobby with your spouse, and discusses the...

Pulling Back the Curtain: Gerald A. Soff, MD

Hear more from our interview with Dr. Soff, where he shares more about his career in hematology, his myeloma diagnosis, and why Sergio Giralt, MD, is...
video

Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML

Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....
video

Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell...

Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.

On Location

Emicizumab Significantly Decreases Bleeding Rate, Compared With No Treatment in Patients With Hemophilia A

In the phase III HAVEN-1 study, preventive treatment with emicizumab significantly reduced bleeding rates, compared...

RNA Interference Therapy Fitusiran Improves Thrombin Generation in Patients With Hemophilia

The investigational RNA interference therapy fitusiran lowered levels of antithrombin in patients with hemophilia A...

Is Anticoagulant Therapy to Prevent Recurrent VTE Worth the Bleeding Risk in Older Patients With Cancer?

Though anticoagulants are common frontline treatment for patients with venous thromboembolism (VTE), patients with cancer...

Phase II Results Show Activity of Polatuzumab Vedotin Combination in DLBCL

The CD79b-targeting antibody drug conjugate polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone...

Evaluating HCT Outcomes in Patients With Beta-Thalassemia

Hematopoietic cell transplantation (HCT) is associated with a disease-free survival rate of 90 percent at...

Fourth Drug’s the Charm? Comparing Combination Therapies in the Myeloma XI Trial

Triplet combinations of anti-myeloma induction therapies lead to deeper, longer remissions than doublet combinations. Results...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

5,241FollowersFollow
4,625SubscribersSubscribe

Can a Post-AHCT, High-Intensity Exercise Program Improve Quality of Life in Patients With Myeloma?

Patients with myeloma who undergo autologous hematopoietic cell transplantation (AHCT) may experience a decline in health-related quality of life (HRQoL). Although exercise has been...
WIB_icon

Fertility Issues in Patients With Inherited Bone Marrow Failure Syndromes

More patients with inherited bone marrow failure syndromes (IBMFS) are surviving to adulthood. As they do, they face barriers to pregnancy. It is still...

New CDC Director Named, NIH Awards Grants for Cancer Cell Metastases, and more

Brenda Fitzgerald Named New Director of the Centers for Disease Control and Prevention Brenda Fitzgerald, MD, the Georgia Public Health Commissioner, has been appointed director...
WIB_icon

Number of Older Patients Receiving AlloHCT Increased Over the Past Decade

Historically, older adults have not been considered optimal candidates for hematopoietic cell transplantation (HCT) because of concerns about transplant-related toxicity and mortality. Over the...
WIB_icon

Examining Nilotinib to Prevent Post-Transplant Relapse in Patients With Ph+ Leukemia

In previous research published in Blood, Paul A. Carpenter, MBBS, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, and co-authors determined that...